Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 11/20 | 0.58 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.50 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.50 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.41 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.40 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.39 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.39 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.39 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.39 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.39 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.38 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25944404 | 0.86 | PGR (0.71) | PGRPDK2PDK4ATAD2PDE3B | |
| SCHEMBL30017975 | 0.79 | PGR (0.41) | PGR | |
| SCHEMBL9865366 | 0.79 | MAPT (0.52) | PGR | |
| SCHEMBL9376592 | 0.79 | PGR (0.51) | PGR | |
| SCHEMBL31219860 | 0.78 | PDK2 (0.45) | PGRPDK2PDK4MAPK14ATAD2 | |
| SCHEMBL9840448 | 0.77 | CYP26A1 (0.48) | MAPK14 | |
| SCHEMBL16322106 | 0.77 | BMPR1B (0.58) | PGRMAPK14BMPR1BBMPR1ATGFBR1 | |
| SCHEMBL19241067 | 0.77 | PGR (0.46) | PGR | |
| SCHEMBL9147351 | 0.76 | RARB (0.61) | PGR | |
| SCHEMBL9376088 | 0.76 | PGR (0.61) | PGRMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023147597-A2 | ALLOSTERIC STING MODULATORS AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2015177110-A1 | INDOLIN-2-ONE AND 1,3-DIHYDRO-PYRROLO[3,2-c]PYRIDIN-2-ONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2015-11-26 | — | — | WO | disclosed |
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PASCALI, PETROS P. (CY) | 2006-05-18 | — | — | US | disclosed |
| EP-1541576-A1 | FUROISOQUINOLINE DERIVATIVE AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2005-06-15 | — | — | EP | disclosed |
| EP-0497852-B1 | BICYCLO-IMIDAZOLES, PROCESS FOR PRODUCING THEM AND DRUGS CONTAINING THEM | BOEHRINGER MANNHEIM GMBH (DE) | 1995-12-20 | — | — | EP | disclosed |
| US-5414088-A | Anticoagluants | BOEHRINGER MANNHEIM GMBH (DE) | 1995-05-09 | — | — | US | disclosed |
| EP-0344634-B1 | Bicyclic carboxamides, process for their preparation and medicaments containing them | BOEHRINGER MANNHEIM GMBH (DE) | 1994-03-30 | — | — | EP | disclosed |
| EP-0497852-A1 | BICYCLO-IMIDAZOLES, PROCESS FOR PRODUCING THEM AND DRUGS CONTAINING THEM. | BOEHRINGER MANNHEIM GMBH (DE) | 1992-08-12 | — | — | EP | disclosed |
| EP-0496753-A1 | 2-BICYCLO-BENZIMIDAZOLES, PROCESS FOR THEIR PRODUCTION AND DRUGS CONTAINING SAID COMPOUNDS | Roche Diagnostics GmbH (DE) | 1992-08-05 | — | — | EP | disclosed |
| US-5019587-A | Anticoagulants | BOEHRINGER MANNHEIM GMBH (DE) | 1991-05-28 | — | — | US | disclosed |
| WO-1991006545-A1 | BICYCLO-IMIDAZOLES, PROCESS FOR PRODUCING THEM AND DRUGS CONTAINING THEM | BOEHRINGER MANNHEIM GMBH (DE) | 1991-05-16 | — | — | WO | disclosed |
| WO-1991004974-A1 | 2-BICYCLO-BENZIMIDAZOLES, PROCESS FOR THEIR PRODUCTION AND DRUGS CONTAINING SAID COMPOUNDS | BOEHRINGER MANNHEIM GMBH (DE) | 1991-04-18 | — | — | WO | disclosed |
| CN-1038640-A | Two ring carboxamide, its preparation methods and contain the pharmaceutical composition of this material | BOEHRINGER MANNHEIM GMBH (DE) | 1990-01-10 | — | — | CN | disclosed |
| EP-0344634-A1 | Bicyclic carboxamides, process for their preparation and medicaments containing them | Roche Diagnostics GmbH (DE) | 1989-12-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060106048-A1 | Furoisoquinoline derivative and use thereof | PDE3B, PDE2A, PDE3A | PGR 1967/4885PDK2 2955/4885PDK4 1916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.